靶向IL-23/IL-17轴的生物制剂治疗中重度斑块状银屑病的系统评价与荟萃分析
结果显示IL-17抑制剂疗效优于IL-23抑制剂,但不良事件风险增加;IL-23抑制剂未增加不良事件风险。
要点
- IL-17抑制剂诱导治疗疗效优于IL-23抑制剂。
- IL-17抑制剂不良事件风险高于安慰剂,IL-23抑制剂未增加风险。
- Ixekizumab每2周一次在达到PASI 90方面疗效最高。
核心结论
- IL-17抑制剂诱导治疗高效但不良事件风险高于IL-23抑制剂。
主要发现
- Ixekizumab每2周一次对比安慰剂达到PASI 90的RR为65.01(95%CI 13.97-302.56,P<0.00001)。
- Ixekizumab每2周一次对比依那西普达到PASI 90的RR为3.14(95%CI 2.22-4.45)。
- Ixekizumab每2周一次对比乌司奴单抗达到PASI 90的RR为1.73(95%CI 1.41-2.12)。
- IL-17抑制剂诱导治疗疗效总体高于IL-23抑制剂。
- IL-17抑制剂不良事件风险高于安慰剂,IL-23抑制剂未增加不良事件风险。
临床怎么用
- 选择诱导治疗时需权衡IL-17抑制剂的高疗效与不良事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There are a rapidly increasing number of novel biologic therapies for psoriasis targeting interleukin-23 (IL-23) and interleukin-17 (IL-17). This systematic review and meta-analysis evaluated the efficacy and safety of induction therapy (12-16 weeks) with biologic therapies targeting the IL-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis. Twenty-seven randomized controlled trials met the specified inclusion criteria. The results showed that ixekizumab q2w had the greatest efficacy in terms of achieving 90% reduction in Psoriasis Area and Severity Index when compared to placebo [risk ratio (RR): 65.01, 95% confidence intervals (CI): 13.97-302.56, P < 0.00001], etanercept (RR: 3.14, 95% CI: 2.22-4.45) and ustekinumab (RR: 1.73, 95% CI: 1.41-2.12). The IL-17 inhibitors were overall shown to have a higher efficacy than the IL-23 inhibitors during induction therapy. However, the IL-17 inhibitors had an increased risk of adverse events when compared to placebo, while there was no increased risk with any of the IL-23 inhibitors. In conclusion, induction therapy with IL-17 inhibitors is highly efficacious but carries a higher risk of adverse events than induction therapy with IL-23 inhibitors.
引用
- Erichsen CY, Jensen P, Kofoed K, et al. Biologic therapies targeting the interleukin (IL)-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019. PMID: 31419343. doi:10.1111/jdv.15879
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。